Dotson et al. reviewed five cases of histoplasmosis in children receiving either infliximab or adalimumab for Crohn’s disease and noted that early diagnosis with discontinuation of anti-TNF medication as well as close follow-up were key to achieving good outcomes [49]. The gene discussed is TNF; the disease is histoplasmosis.